Anti-stigma Intervention for Chinese American Older Adults

NCT03820297 | Completed

• 1 other identifier: 18-01236
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

Approximately 50 participants will be enrolled and screened to achieve 45 eligible patients with mood/anxiety disorders to complete a 10 weekly anti-stigma group intervention (ASGI) in addition to several self-report internalized stigma and psychiatric measures.This study will examine changes in internalized stigma and psychiatric symptoms pre- and post-ASGI with 3 months post-intervention follow-up.

Conditions

Mood Disorders; Anxiety Disorders

Outcome Measures

Primary Outcomes (3)

• Self stigma of mental illness scale

  This 40-item self-report scale assesses the extent of patient self-stigma. Items are rated on a 9-point Likert-type scale (1= Strongly Disagree; 9= Strongly Agree). Total score from 1 to 9 (average score) Higher score means worse outcome

  23 weeks

• Recovery assessment scale

  Empowerment will be assessed using the 15-item scale from the Recovery Assessment Scale. This scale measures domains of recovery including 1) personal confidence and hope 2) willingness to ask for help 3) goal and success orientation 4) reliance on others 5) symptom coping. Patients are asked to describe themselves using a 5-point agreement scale (1= strongly disagree, 5= strongly agree) regarding their recovery. Total score from15 to 75 (summed score) Higher score means better outcome

  23 weeks

• Self-protective Withdrawal and Secrecy scale

  Changes in use of self-protective withdrawal and secrecy as a strategy for coping with public stigma will be evaluated using two scales to assess patients' responses to their stigmatized status. 1. Secrecy subscale: a 5-item Likert-type scale (1=strongly agree, 6=strongly disagree) assessing use of concealment of mental illness. Total score: 5 to 30 (summed score) 2. Withdrawal subscale consists of 7 items (1=strongly agree, 6=strongly disagree) assessing "limiting social interaction to those who know about and tend to accept one's stigmatized condition". Total score: 6 to 42 (average score). For the overall scale, summed score will be used. Higher score means better outcome

  23 weeks

Secondary Outcomes (3)

• Changes in social support

  23 weeks

• Changes in patient depressive symptoms measured by Patient Health Questionnaire-9 (PHQ-9)

  23 weeks

• Changes in patient anxiety symptoms associated with stigma reduction

  23 weeks

Study Arms (1)

Anti-Stigma Group

OTHER

Complete a 10 weekly anti-stigma group intervention (ASGI) in addition to several self-report internalized stigma and psychiatric measures.

Behavioral: 10 sessions of ASGI

Interventions

10 sessions of ASGI BEHAVIORAL

10-session intervention will occur weekly for 45 minutes per session: psychoeducation about mood and anxiety disorders, focusing on identification of risk factors and biological theory to counter stigma; psychoeducation regarding 'therapeutic modules' (psychotropics and psychotherapy) to treat depression, with an emphasis on the importance of psychiatric treatment adherence, providing behavioral strategies for anticipated and experienced forms of mental illness related work, social, or family discrimination

Anti-Stigma Group

Eligibility Criteria

• Age: 55 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Self-reported Chinese heritage;
• years or older
• Mandarin and/or Cantonese speaking and ability to read and/or comprehend spoken Chinese language.
• Currently receiving treatment from a mental health provider at Gouverneur Medical Center Asian Bicultural Clinic (GMC ABC) and willing to continue mental health care through the study.
• Willing to provide release for communication between primary mental health care provider and study staff throughout the study.
• Documented by mental health provider after consent for release of information as having mood and anxiety disorder diagnosis in the past year;
• A willingness to participate in the ASGI with stated availability;
• Able and willing to provide informed consent.

You may not qualify if:

• Lifetime psychosis, neurocognitive, or significant neurological disorders;
• Current manic episode;
• Past 6 months of alcohol/substance use disorder;
• Serious safety concerns of suicide or homicide.

Sponsors & Collaborators

• NYU Langone Health: lead
• Substance Abuse and Mental Health Services Administration (SAMHSA): collaborator

Study Sites (1)

New York University School of Medicine

New York, New York, 10016, United States

Location

MeSH Terms

Conditions

Mood Disorders; Anxiety Disorders

Condition Hierarchy (Ancestors)

Mental Disorders

Study Officials

• Naomi Simon, MD

  NYU Langone Health

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 25, 2019
• First Posted: January 29, 2019
• Study Start: August 19, 2019
• Primary Completion: March 13, 2020
• Study Completion: March 13, 2020
• Last Updated: May 20, 2020

Record last verified: 2020-05

Locations

US (1)